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Abstract
Introduction: Itraconazole is an anti-fungal agent widely used to treat various forms of mycosis. It is particularly
useful in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. Side effects are
uncommon and usually mild. Mild neuropathy is noted to occur very rarely. We present an unusual and, to the
best of our knowledge, as yet unreported case of severe neuropathy and peripheral edema due to itraconazole in
the absence of a concomitant risk factor.
Case presentation: A 72-year-old Caucasian man was started on itraconazole following diagnosis of severe asthma
with fungal sensitization. One month later he presented with severe bilateral ankle edema with an elevated serum
itraconazole level. The itraconazole dose was reduced but his ankle edema persisted and he developed weakness
of all four limbs. Itraconazole was completely stopped leading to improvement in his leg edema but he became
bed bound due to weakness. He gradually improved with supportive care and neurorehabilitation. On review at six
months, our patient was able to mobilize with the aid of two elbow crutches and power had returned to 5/5 in
distal extremities and 4+/5 in proximal extremities. The diagnosis was established based on the classical
presentation of drug-induced neuropathy and negative investigatory findings for any alternative diagnoses.
Conclusion: We report the case of a patient presenting with an unusual complication of severe neuropathy and
peripheral edema due to itraconazole. Clinicians should be alert to this association when encountered with
neuropathy and/or edema in an itraconazole therapy recipient.
Introduction
Itraconazole is an anti-fungal agent that was registered
for use in 1991. It is widely used to treat several forms
of mycosis. It was the first oral agent with activity
against Aspergillus species [1]. It is also effective in aller-
g i cb r o n c h o p u l m o n a r ya s p e r gillosis (ABPA) and in the
n e w l yd e s c r i b e ds y n d r o m e ,s e v e r ea s t h m aw i t hf u n g a l
sensitization (SAFS) [2,3]. Side effects are uncommon
(less than 7%) and usually mild [4-6]. Mild peripheral
neuropathy is reported with a frequency of less than
one in 10,000 [4]. Numerous case reports of itracona-
zole-enhanced vincristine neuropathy exist and are
attributed to reduced vincristine metabolism by itraco-
n a z o l e[ 7 - 9 ] .W er e p o r tau n i q u ec a s eo fs e v e r e
neuropathy due to itraconazole in the absence of a con-
comitant risk factor.
Case presentation
A 72 year-old Caucasian man had been on treatment for
many years for severe asthma with relatively good exer-
cise tolerance. Over a period of two years he developed
increasing shortness of breath and productive cough
necessitating assessment in a specialist immunology
clinic. His total immunoglobulin E (IgE) was 680kIU/L
and specific IgE against Aspergillus fumigatus was
14.6kUa/L. Precipitins against A. fumigatus were weakly
positive (titre 1/2) without a peripheral eosinophilia.
Computerized tomography revealed marked emphysema
and mild bronchiectasis. Based on these results he was
diagnosed with SAFS and itraconazole was commenced
(Sporanox™ 200 mg twice daily). His only other medi-
cines were formoterol fumarate (6 mg inhaler, one puff
twice daily), fluticasone (500 mg inhaler, one puff twice
daily) and nebulized salbutamol (2.5 mg twice daily).
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ankle edema (Figure 1). The itraconazole level by bioas-
say was 17.5 mg/L (therapeutic range 5-15 mg/L) and
the dosage was reduced to 200 mg once daily. A month
later, peripheral edema persisted and he developed
weakness of all four limbs. There were no signs of heart
failure and the itraconazole level was 9.8 mg/L. Itraco-
nazole was completely stopped leading to improvement
in leg edema but limb weakness persisted. After six
weeks he had become bed bound and he was referred to
the tertiary neurology centre.
On admission, he had mild bil a t e r a lf a c i a lw e a k n e s s .
Tone was normal in his upper limbs but reduced in
both his lower limbs. There was a grade 2-3/5 global
weakness in both his lower limbs and grade 3/4 global
weakness in both his upper limbs. He was areflexic in
all four limbs. His vibration sense was absent up to his
tibial tuberosity, joint position sense impaired up to the
level of his metatarsal joint and pinprick sensation
reduced to his mid-shin level.
Nerve conduction studies revealed globally attenuated
motor and sensory responses without slowing, in keep-
ing with a marked sensory and motor axonal polyneuro-
pathy. Blood tests were mostly normal including a
normal creatine kinase level. His lactase dehydrogenase
level was mildly elevated at 490IU/L (reference range
105-333IU/L) and C-reactive protein level was 21 mg/L
(reference range 0-10 mg/L). His thyroid function was
normal and serum albumin level was modestly reduced,
ranging from 23 to 29g/L during the illness. A sural
nerve biopsy revealed mild axonal neuropathy and some
evidence of regeneration, without evidence of vasculitis.
A muscle biopsy (tibialis anterior) showed features con-
sistent with an underlying neurogenic process (denerva-
tion related changes) and there was no evidence of
vasculitis. Results from the examination of his cere-
brospinal fluid (CSF) were normal with <1 leucocyte/μL,
glucose 4.8 mmol/L and protein 0.4 g/L.
No immunoglobulin G (IgG) anti-nuclear, extractable
nuclear, smooth muscle, mitochondrial, reticular, gastric
parietal, para-neoplastic neuronal specific, acetylcholine
receptor, perinuclear-staining anti-neutrophil cytoplas-
mic antibodies (p-ANCA) or cytoplasmic-staining anti-
neutrophil cytoplasmic antibodies (c-ANCA) were
detected in his blood. The erythrocyte sedimentation
rate was 70 mm/h (range 0-65 mm/h). His repeat total
IgE was 236kIU/L with Aspergillus specific IgE reduced
to 6.84kUa/L (previously 14.6 kUa/L), consistent with a
good response to itraconazole. Although in the initial
differential, axonal Guillain-Barré syndrome (GBS) was
considered, the results of the investigations, particularly
CSF protein, and the subsequent disease course made
the diagnosis of itraconazole-induced neuropathy most
likely.
Our patient received supportive care initially followed
by active neurorehabilitation. Gradual improvement
occurred over a two-month period and our patient was
discharged. He was reviewed in clinic six months after
his discharge, and was able to mobilize with the aid of
two elbow crutches. The power had returned to 5/5 in
his distal upper and lower extremities and 4+/5 in his
proximal upper and lower extremities.
Figure 1 Gross peripheral edema during itraconazole therapy.
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Itraconazole is a synthetic triazole anti-fungal agent,
which was first discovered in 1980 and licensed in 1991
for the treatment of invasive aspergillosis and several
endemic mycoses, such as histoplasmosis and sporotri-
chosis. It has been extensively used for a variety of aller-
gic, cutaneous and systemic mycoses and in treatment
as well as prophylaxis of fungal infection in hematologi-
cal and transplant patients [1].
In recent years, itraconazole has been increasingly
used for treating ABPA and, very recently, the newly
described syndrome SAFS [2,3]. Generally, itraconazole
is well tolerated with only mild side effects reported
[4-6]. In clinical studies the overall incidence of adverse
events is in the order of 7% with short-term use, and up
to 15% with long-term use - the gastrointestinal side
effects being the most common [4,6]. Ankle edema is an
uncommon complication of therapy with itraconazole
[7]. It is reported in up to 4% of patients in clinical
trials, being more common in patients receiving calcium
channel blockers. The mechanism for this side effect
remains unknown. Marked edema requiring drug sus-
pension as seen in our case is a rare phenomenon and
has been reported only once before [7]. Although,
hypoalbuminemia (range 23-29g/L) was present, possibly
aggravating the edema, this would not on its own be
expected to give rise to the very marked edema that was
observed in our case.
Itraconazole is a rare cause of peripheral neuropathy
with a reported frequency of less than 1 out of 10,000
in the product data sheet [4]. Interestingly, there are
several reports of itraconazole-enhanced vincristine neu-
rotoxicity [8-10] and one report of painful neuropathy
in a Type 1 diabetes mellitus patient [11]. However,
severe neuropathy solely due to itraconazole without
any concomitant risk factor, as in our case, has not been
reported thus far.
Among the other azole drugs, there are at least four
case reports of voriconazole causing painful peripheral
neuropathy in the literature [12-14]. Posaconazole,
despite being a highly lipophilic drug, has not been
reported as an exclusive cause of neuropathy but evi-
dence exists that it enhances vincristine-induced neuro-
toxicity [15,16].
Several features support the diagnosis in our case.
Firstly, the temporal association between onset of ankle
edema and neuropathy after commencing itraconazole,
and gradual recovery upon stopping the drug, is very
suggestive. The time and dose dependent pattern of
axonal sensorimotor polyneuropathy, as seen in our
case, is characteristic of drug-induced neuropathy [17].
Although the clinical features could represent the axonal
variant of GBS, the normal CSF protein would be
against this, as would the contemporaneous onset of
ankle edema, a known side effect of itraconazole and
not a feature of GBS. The only similarities noticed
between vincristine associated neuropathy cases and our
case are the presence of large fiber sensory loss, signifi-
cant motor involvement, normal CSF findings and gra-
dual recovery upon stopping the drug. The previous
reports of neuropathy caused by combined treatment
with vincristine and itraconazole mostly describe a form
of rapidly progressing paresthesia and/or muscle weak-
ness and paralytic ileus [8-10]. In all the above cases
there was gradual neurological improvement upon stop-
ping the causative drugs that is also evident in our case.
The possible mechanism for neuropathy due to itraco-
nazole is speculative. Itraconazole is a cytochrome inhibi-
tor with strong lipophilicity and high plasma protein
binding ability (99%) [18,19]. The characteristic tissue
penetrability manifests in a tissue concentration, two- to
ten-fold higher than the plasma concentration. This has
been deduced as the reason for its efficacy despite a very
low plasma itraconazole concentration in some indivi-
duals. Conversely, in our patient, a high initial plasma itra-
conazole concentration would have led to substantial
tissue saturation leading to neurotoxicity, and the subse-
quent slow clearance would account for the gradual recov-
ery despite early drug discontinuation [20]. An additional
mechanism relevant to our case is the ‘active efflux system’
in brain described by Miyama and colleagues [21]. Accord-
ingly, itraconazole if present at low concentration in brain
undergoes faster elimination and when present at high
concentration undergoes slower elimination. The latter
scenario would be pertinent to our case.
It is notable in our case that initial itraconazole levels
were high despite standard dosing. This is explained by
the fact that itraconazole levels are not only dose depen-
dent but can significantly vary in individuals receiving
the same dose, probably reflecting its hepatic metabo-
lism and enterohepatic circulation [22]. Hence, initial
dosing cannot predict the steady state plasma concen-
tration. It is conceivable that higher levels would lead to
higher tissue saturation and are more likely to cause
neuropathy. Consequently, we would advise monitoring
the levels following initial dosing with this drug and
further monitoring if any dose increments are made.
Conclusion
We report, what we believe to be the first case of severe
neuropathy and ankle edema due to itraconazole in the
absence of a concomitant risk factor. Clinicians should
be alert to this association when encountering neuropa-
thy and/or edema in an itraconazole therapy recipient.
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